Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Videos|October 10, 2025

BioPharm Weekly News Roundup—Week of Oct. 6, 2025

Scaling biopharma innovation demands advanced manufacturing, global market expansion, and solving patient access barriers.

Welcome to the BioPharm International® weekly news roundup for the week of Oct. 6, 2025. In this video feature, the editors highlight each week’s industry news in an easy-to-consume, fun format. New roundups will drop every Friday, so be sure to come back each week. And be sure to check the links below for more in-depth coverage of each story.

RedHill’s $1.8 million deal licenses FDA-approved Talicia (omeprazole magnesium, amoxicillin and rifabutin) to fight widespread Helicobacter pylori antibiotic resistance and gastric cancer risk in Middle East markets.

Prime editing offers safe, precise genome correction, offering innovative delivery methods that are essential to overcome tissue targeting hurdles like cystic fibrosis.

Big biopharma investment drives cell and gene therapy (CGT) scale, expanding applications beyond oncology and securing infrastructure needed for manufacturing consistency and patient access.

Rentschler Biopharma expands into Japan and South Korea, offering new platforms to accelerate specialized biologics development and manufacturing services in Asia.

Mainstreaming chimeric antigen receptor T cell therapy requires decentralizing care, reforming quality standards, and scaling manufacturing via a pivotal shift to allogeneic processes.

CGT 2.0 requires modular platforms, automation, and collaboration for simultaneous flexibility and scalability, ensuring affordable commercial viability and patient access.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more